Abstract 1159P
Background
The clinical presentation of patients (pts) diagnosed with melanoma of unknown primary (MUP) is not clearly known, like their therapeutic assignment and their evolution in terms of responses obtained, toxicity, and relapse profile in the actuality.
Methods
GEM1801 is a prospective observational study including pts with melanoma that analyzes the clinical and pathological disease presentation patterns, the different lines of treatment choices and the health outcomes derived from treatments. Here we focus on the clinical and evolution characterization of pts diagnosed with MUP.
Results
From Aug 2018 to Dec 2022, 893 evaluable pts were enrolled, 133 (14.9%) being MUP. Median age was 63 years (range 24-93), 81 (60.9%) male. Distal metastases were present in 117 (88%) pts with most (50.4%) having ≥ 3 affected organs, including ganglia (53.4%), lung (41.4%) or brain (30.1%). LDH was elevated in 50 (37.6%) pts. BRAF was mutated in 79 (54.9%) pts. Adjuvant therapy was administered to 28 (21.1%) pts with MUP, being immunotherapy less frequently prescribed than in pts with known primary (17.3% vs 27.1%; p=0.017). Immunotherapy was also less frequent for the 1st line in the metastatic/locally advanced setting (53.6% vs 64%; p=0.039). Conversely, more pts with MUP were enrolled in clinical trials exploring combo of immunotherapy and targeted therapy (9.1% vs 4.8%; p=0.074). Table: 1159P
N, (%) | Median PFS (95% CI), months | Median OS (95% CI), months | |
BRAF + IT | 17 (12.8) | 18.9 (4.4-NR) | 24.9 (24.1-NR) |
BRAF + TT | 40 (30.1) | 13.3 (7.1-27.5) | 13.9 (8.3-NR) |
BRAF - IT | 41 (30.8) | 6.7 (3.5-NR) | 17.9 (9.6-NR) |
IT = Immunotherapy; TT = Targeted therapy.
Conclusions
MUP in Spain comprises a population with a multiorgan presentation and frequent brain metastasis, which was followed by worse outcomes than the general melanoma population. Having MUP diagnosis seems to influence the therapeutic assignment, specially for immunotherapy schemes.
Clinical trial identification
NCT03605771.
Editorial acknowledgement
We acknowledge MFAR Clinical Research staff for their assistance in the development of this abstract.
Legal entity responsible for the study
Grupo Español Multidisciplinar de Melanoma (GEM).
Funding
GEM through industry partners Novartis, Pierre Fabre, Incyte, BMS, Roche y MSD.
Disclosure
E. Muñoz-Couselo: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Novartis, Pierre Fabre, Sanofi, Roche; Other, Personal, Advisory Board: Amgen, BMS, MSD, Novartis, Pierre Fabre, Roche, Sanofi; Other, Personal, Other, Honoraria: Amgen, BMS, Novartis, Pierre Fabre, Roche; Other, Personal, Principal Investigator: Amgen, BMS, GSK, MSD, Novartis, Pierre Fabre, Roche, Sanofi. E. Espinosa: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, Novartis, Pierre Fabre; Financial Interests, Personal, Advisory Role: MSD. L.A. Fernández-Morales: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Pierre Fabre, Roche, Novartis, Pfizer. T. Puértolas: Financial Interests, Personal, Advisory Role: Bristol Myers Squibb, Immunocore, Novartis, Seagen; Other, Personal, Other, Travel, Accommodation, Expenses: Novartis, MSD, Pierre Fabre. I. Márquez-Rodas: Financial Interests, Personal, Advisory Board: BMS, MSD, Novartis, Pierre Fabre, Roche, GSK, AstraZeneca, Celgene, Regeneron, Sanofi, Merck Serono, Highlight Therapeutics, Bioline Rx, Sun Pharma, Immunocore; Financial Interests, Personal and Institutional, Coordinating PI: Pierre Fabre; Financial Interests, Institutional, Coordinating PI, GEM1802 clinical trial: Novartis; Financial Interests, Institutional, Coordinating PI, GEM1801 clinical study: BMS, Roche, Pierre Fabre, Incyte, MSD; Financial Interests, Institutional, Coordinating PI, National coordinator of Spotlight 203 clinical trial: Highlight Therapeutics; Non-Financial Interests, Advisory Board: Spanish Melanoma group. All other authors have declared no conflicts of interest.
Resources from the same session
1100P - Open-label non-randomized phase IB study to characterize the safety, tolerability and recommended dose of tinostamustin in combination with nivolumab in patients with advanced melanoma (ENIGMA)
Presenter: Markus Joerger
Session: Poster session 13
1101P - The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Presenter: Jordi Rodon
Session: Poster session 13
1102P - Evaluation of surrogate endpoints for overall survival within the RELATIVITY-047 trial
Presenter: Peter Mohr
Session: Poster session 13
1103P - Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year subgroup analyses from RELATIVITY-047
Presenter: Georgina Long
Session: Poster session 13
1104P - Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment: A EUMelareg real-world evidence study
Presenter: Michael Weichenthal
Session: Poster session 13
1105P - First-line nivolumab plus ipilimumab in advanced melanoma patients previously treated with adjuvant systemic therapy
Presenter: Katarzyna Kozak
Session: Poster session 13
1106P - Anti-PD-1 (PD1) monotherapy or in combination with anti-CTLA-4 for metastatic melanoma (MM) patients (pts) with liver metastases (mets)
Presenter: Ines Pires da Silva
Session: Poster session 13
1107P - BRAF mutation status does not impact outcomes with tebentafusp in advanced cutaneous melanoma
Presenter: Alexander Shoushtari
Session: Poster session 13
1108P - Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete response or toxicities
Presenter: Nur Sakinah Zulkifli
Session: Poster session 13